Skip to content

The Impact of Serial Remote Ischemic Conditioning on Dynamic Cerebral Autoregulation in Healthy Adults

The Impact of Serial Remote Ischemic Conditioning on Dynamic Cerebral Autoregulation in Healthy Adults

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04899362
Enrollment
36
Registered
2021-05-24
Start date
2021-05-20
Completion date
2021-07-30
Last updated
2024-01-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Remote Ischemic Conditioning

Keywords

Remote Ischemic Conditioning, Dynamic Cerebral Autoregulation

Brief summary

The purpose of this study is to determine the impact of serial remote ischemic conditioning on dynamic cerebral autoregulation and related hematology indexes in healthy adults.

Detailed description

Remote ischemic conditioning(RIC) is the phenomenon whereby brief cycles of ischemia and reperfusion, applied to a distant organ, provide protection to the target organ. Dynamic cerebral autoregulation(dCA), a mechanism to maintain the cerebral blood flow, has been proved to be critical for the occurrence,development and prognosis of ischemic neurovascular disease. In this study, we hypothesis that RIC provides neuro-protection by means of improving dCA.

Interventions

DEVICEBB-RIC-D1/LAPUL Medical Devices Co, Ltd, China

The RIC consisted of 4 cycles of extremities ischemia (5-minute blood pressure cuff inflation to 200 mm Hg, followed by 5-minute cuff deflation). The tourniquets were applied to one side upper arm. This intervention was undertaken twice a day for 7 days.

Nurses will collect intravenous blood 3ml four times (at baseline and the first, seventh and eighth day of the study).The blood samples will be stored for laboratory test.The blood samples only use for the trial.

Serial measurements of dCA were performed at 10 days, baseline, 1st, 2ed, 4th, 7th, 8th, 10th, 14th, 21th and 35th of the study.The continuous ABP was measured non-invasively using a servo-controlled plethysmograph (Finometer Pro, the Netherlands) at the middle finger. Two 2 MHz transcranial Doppler probe was used to measure continuous cerebral blood flow velocity (CBFV) simultaneously in the bilateral middle cerebral arteries at a depth of 45-60 mm Endtidal CO2 was monitored using a capnograph (MultiDop X2, DWL, Sipplingen, Germany). The probes were placed over temporal windows and fixed with a customized head frame. CBFV and continuous arterial blood pressure were recorded simultaneously from each subject in the supine position for 10 minutes. All data were recorded for further assessment and analysis.

Sponsors

The First Hospital of Jilin University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* age from 18 to 50,both genders * willing to participate in follow-up visits

Exclusion criteria

* current or having a history of chronic physical diseases or mental diseases * suffering from infectious diseases in late one month * pregnant and lactating women# * smoking or drinking# * inability to cooperate sufficiently to complete the dCA examination

Design outcomes

Primary

MeasureTime frameDescription
Dynamic Cerebral Autoregulation Parameter: Phase Difference(PD) in Degree36 daysDynamic cerebral autoregulation (dCA) is an important indicator of cerebrovascular function which related to the prognosis of cerebrovascular disease. DCA is usually calculated by transfer function analysis. Phase Difference (PD) is gengreated. Low PD at a low frequency band indicates impairment of autoregulation, as it suggests that cerebral blood flow velocity follows the changes in arterial blood pressure with a short delay.

Secondary

MeasureTime frameDescription
Dynamic Cerebral Autoregulation Parameter: Gain in cm/s/mmHg36 daysHigh gain at the same frequency band is also considered an indicator of compromised autoregulation for passively transferring the amplitude of arterial blood pressure to cerebral blood flow velocity.

Countries

China

Participant flow

Participants by arm

ArmCount
RIC Group
RIC was induced by 4 cycles of extremities ischemia (5-minute blood-pressure cuff inflation to 200 mm Hg, followed by 5-minute cuff deflation).All subjects will take 14 RIC intervention, blood collection and 10 dCA measurements.
22
Total22

Baseline characteristics

CharacteristicRIC Group
Age, Continuous25.73 years
STANDARD_DEVIATION 1.78
BMI20.88 kg/m^2
STANDARD_DEVIATION 2.1
Height164.50 cm
STANDARD_DEVIATION 8.36
Race and Ethnicity Not Collected— Participants
Sex: Female, Male
Female
19 Participants
Sex: Female, Male
Male
3 Participants
Weight56.81 kg
STANDARD_DEVIATION 9.42

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 36
other
Total, other adverse events
0 / 36
serious
Total, serious adverse events
0 / 36

Outcome results

Primary

Dynamic Cerebral Autoregulation Parameter: Phase Difference(PD) in Degree

Dynamic cerebral autoregulation (dCA) is an important indicator of cerebrovascular function which related to the prognosis of cerebrovascular disease. DCA is usually calculated by transfer function analysis. Phase Difference (PD) is gengreated. Low PD at a low frequency band indicates impairment of autoregulation, as it suggests that cerebral blood flow velocity follows the changes in arterial blood pressure with a short delay.

Time frame: 36 days

ArmMeasureValue (MEAN)Dispersion
RIC GroupDynamic Cerebral Autoregulation Parameter: Phase Difference(PD) in Degree45.87 degreeStandard Deviation 13.02
Secondary

Dynamic Cerebral Autoregulation Parameter: Gain in cm/s/mmHg

High gain at the same frequency band is also considered an indicator of compromised autoregulation for passively transferring the amplitude of arterial blood pressure to cerebral blood flow velocity.

Time frame: 36 days

ArmMeasureValue (MEAN)Dispersion
RIC GroupDynamic Cerebral Autoregulation Parameter: Gain in cm/s/mmHg0.95 cm/s/mmHgStandard Deviation 0.25

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026